Triclabendazole in the treatment of human fascioliasis: a community-based study
EMHJ-Eastern Mediterranean Health Journal. 1999; 5 (5): 888-894
in English
| IMEMR
| ID: emr-156679
ABSTRACT
The efficacy of triclabendazole in the treatment of chronic Fasciola infection was assessed. A total of 134 asymptomatic cases of established Fasciola infection were treated 68 individuals received a single dose of 10 mg/kg and 66 individuals received 2 doses of 10 mg/kg on 2 consecutive days. Cure was assessed 5 weeks after treatment and 79.4% of the first group and 93.9% of the second group were cured. The drug was well tolerated; no serious side-effects were noted. One patient developed biochemical cholestasis the third day after treatment, but her enzyme profiles returned to normal after 2 months. We conclude triclabendazole is a safe and potent fasciolicidic drug
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Benzimidazoles
/
Drug Administration Schedule
/
Child, Preschool
/
Cholestasis
/
Chronic Disease
/
Treatment Outcome
/
Endemic Diseases
/
Liver Function Tests
/
Anthelmintics
Limits:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
/
Male
Language:
English
Journal:
East Mediterr Health J.
Year:
1999
Similar
MEDLINE
...
LILACS
LIS